In Reply We appreciate the comments from Rassy et al on our Brief Report.1 We completely agree that caution is needed in interpreting our findings given the challenges of analyzing, grading, and attributing immune-related adverse events, particularly regarding the exact percentages and duration of symptom persistence. Further studies with extended duration of follow-up (eg, ≥5 years) will be needed to provide more accurate characterization.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Johnson DB, Patrinely JR, Ye F. Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events—Reply. JAMA Oncol. 2021;7(10):1574–1575. doi:10.1001/jamaoncol.2021.2957
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.